The company reported the previous year's revenue of 42.62
K. Net Loss for the year was (18.2
M) with profit before overhead, payroll, taxes, and interest of 23.26
K. About
13.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.15. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Ocugen Inc recorded a loss per share of
427.27. The entity had not issued any dividends in recent years. The firm had
a split on the 30th of September 2019.
The performance of Ocugen Inc in the marketplace will significantly impact your decision to invest in its stock. Revenue growth, profitability, competitive positioning, management quality, and industry trends can influence Ocugen's
stock prices. When investing in Ocugen, there are several factors to consider and potential outcomes to expect. As a company performs well, its stock price may increase, allowing investors to benefit from price appreciation. However, Ocugen Stock can experience significant price fluctuations due to market conditions, economic factors, industry trends, or company-specific news. This is why investing in stocks such as Ocugen carries risks, including the potential for capital loss. Stock prices can decline, and investors may incur losses if they sell shares at a lower price than their initial investment.
Watch out for price decline
Please consider monitoring Ocugen on a daily basis if you are holding a position in it. Ocugen is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Ocugen stock to be traded above the $1 level to remain listed. If Ocugen stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How important is Ocugen's Liquidity
Ocugen
financial leverage refers to using borrowed capital as a funding source to finance Ocugen Inc ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Ocugen financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Ocugen's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Ocugen's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Ocugen's total debt and its cash.
Ocugen Gross Profit
Ocugen Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Ocugen previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Ocugen Gross Profit growth over the last 10 years. Please check Ocugen's
gross profit and other
fundamental indicators for more details.
What is driving Ocugen Investor Appetite?
Ocugen Inc has a total of 187.05 Million outstanding shares. Ocugen holds 3.26 pct. if its
outstanding shares held by
insiders and 3.26 pct. owned by
third-party entities . Remember, it does not matter who owns the company or if the company is currently
losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Ownership Breakdown
| Retail Investors83.62% | | Institutions13.12% |
| Retail Investors | 83.62 |
| Insiders | 3.26 |
| Institutions | 13.12 |
Can Ocugen build up on the latest rise?
Ocugen latest semi deviation surges over 7.61. Ocugen Inc is showing large volatility of returns over the selected time horizon. We encourage all investors to investigate this asset further to make sure related market timing strategies are aligned with all the expectations about Ocugen implied risk. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Ocugen's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Ocugen's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
The Bottom Line
Whereas many of the other players within the biotechnology industry are still a little expensive, even after the recent corrections, Ocugen may offer a potential longer-term growth to institutional investors. In closing, as of the 27th of February 2021, our concluding 30 days advice on the company is
Cautious Hold. We believe Ocugen is currently
overvalued with
below average odds of financial distress for the next two years.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Ocugen Inc. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
